Parkinson’s Disease

As a chronic neurodegenerative disease affecting the CNS, Parkinson’s Disease present progressive symptoms such as slow movements, tremor, muscle stiffness and cognitive impairment. 

Parkinson’s Disease is a synucleopathic disease. It is a consequence of the loss of dopaminergic neurons associated with the anatomopathological landmark, the presence of Lewy Bodies, that are intracellular aggregation of proteins. Among these proteins can be found the Synuclein, the Ubiquitin and many others. Besides the loss of dopaminergic neurons in Parkinson’s Disease, there is the loss of a number of brain areas.

Parkinson’s Disease Assays and models

in vitro models

  • Neuroservice, our member expert in cell and slice electrophysiology, proposes:
    • Slice electrophysiology assays on PD models
    • Electrophysiology recordings from iPSC-derived neurons from PD patients

in vivo models

  • Key-Obs, our expert in behavioural models of neurological disorders, offers behavioural tests to assess compound efficacy on pharmacological PD models (6-OHDA)
  • Our expert platform Motac, specialized in providing new technologies to develop therapies for NDDs, provides all types of genetic or pharmacologically-induced PD models in rodents or NHPs, as well as cognitive performance tests in aged NHPs

Are you currently working on compounds targeting Parkinson’s Disease?

Please contact us for any additional information and we will gladly come back to you. We can also set up a dedicated meeting between you and our experts to discuss our CRO services and your research needs.

Jean-Charles BIZOT, PhD
CEO & Behavioral Pharmacologist
KEY-OBS
Fabrice TROVERO,PhD
GM & Behavioral Pharmacologist
KEY-OBS
Erwan BEZARD, PhD
CSO, AD/PD expert
MOTAC
Bruno BUISSON, PhD
Co-Founder, President & CSO
NEUROSERVICES-ALLIANCE
& NEUROSERVICE
Bob PETROSKI, PhD
Scientific liaison
NEUROSERVICES-ALLIANCE
Jeffrey HUBBARD, PhD
Head of Patch-Clamp laboratory
NEUROSERVICE